Mologic is developing rapid diagnostic reagent products and technology. The company has advanced a 10-product portfolio with two products introduced in Q1 2017. The remaining products will be launched during 2017 and 2018, culminating in the completion of the world’s first respiratory disease exacerbation monitor.
Underpinning the new product development pathway, Mologic continues to deliver high value contract partnering projects for a range of national and international clients. The company’s broad range of skills and experience, including a low-volume manufacturing facility (ISO13485 certified) enable the business to take on almost any project challenge, irrespective of size, complexity or stage. Through Mologic’s professional partnerships, successful products can achieve high volume manufacturing, distribution and regulatory support across the globe.
Mologic’s interests extend beyond human healthcare, with active programs on large animal disease diagnostics and vaccine innovation, exploiting the advances in technology from the human sector.